#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Penile squamous cell carcinoma Acute respiratory distress syndrome Hypomagnesaemia Leiomyosarcoma Ependymoma Immune-mediated enterocolitis Progressive multifocal leukoencephalopathy Spinal cord injury cervical SAPHO syndrome Oesophageal squamous cell carcinoma stage III Sickle cell disease Hyperchylomicronaemia Haemophilia Cholangiocarcinoma Angiosarcoma More trials…

    Learn about Rare Diseases

    Anaplastic thyroid cancer – Diagnostics Gaucher’s disease type III – Basic Information Noonan syndrome – Basic Information Congenital hypotransferrinaemia – Treatment Mucopolysaccharidosis III – Life with Disease Paraneoplastic neurological syndrome – Diagnostics Hepatic angiosarcoma – Diagnostics Erdheim-Chester disease – Life with Disease Lysosomal storage disorder – Trials in Disease Crigler-Najjar syndrome More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Nortriptyline Leflunomide Lt3001 Azd7798 Febuxostat Hemihydrate Ontasameran Zasocitinib Capsaicin PF-07868489 Calcitriol Benralizumab Cladribine Cilastatin Sodium Azenosertib Plitidepsin Sodium Iodide (131I) Radotinib Dihydrochloride Sparsentan Haemophilus Influenzae Trastuzumab Deruxtecan More therapies…

    Learn about Your Condition

    Head and neck cancer stage IV Post-acute COVID-19 syndrome Rabies Cutaneous T-cell lymphoma Sarcoma CADASIL Hepatobiliary disease Cystic fibrosis Medulloblastoma recurrent Fungal infection Skin disorder Eye pain Infertility female Hepatic angiosarcoma Traumatic pain More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

ABM

  • A study comparing BNT113 combined with pembrolizumab versus pembrolizumab alone for patients with HPV16-positive head and neck cancer that cannot be removed by surgery

    Recruiting

    4 1 1 1
    Investigated Diseases:
    • Squamous cell carcinoma of head and neck
    Investigated Drugs:
    • Rbl015.2
    • Rbl016.2
    • Pembrolizumab
    Austria Belgium Czechia France Germany Hungary +5

  • A study testing GSK3862995B compared to placebo for safety and effectiveness in adults aged 18 to 85 years with bronchiectasis

    Recruiting

    2 1
    Investigated Diseases:
    • Bronchiectasis
    Investigated Drugs:
    • GSK3862995B
    Denmark France Germany Italy Poland Spain

  • A study testing ACT-1004-1239 compared to placebo for adults with progressive multiple sclerosis to measure nerve repair using MRI scans

    Recruiting

    2 1
    Investigated Diseases:
    • Progressive multiple sclerosis
    Investigated Drugs:
    • ACT-1004-1239
    The Netherlands

  • Study of glepaglutide compared to placebo for patients with short bowel syndrome with intestinal failure

    Recruiting

    3 1
    Investigated Diseases:
    • Short-bowel syndrome
    Investigated Drugs:
    • Glepaglutide
    Austria Belgium Czechia Denmark Estonia Finland +9

  • A study comparing under-the-skin and into-the-vein alpha1-proteinase inhibitor treatment in patients with alpha1-antitrypsin deficiency

    Recruiting

    3 1 1
    Investigated Diseases:
    • Alpha-1 antitrypsin deficiency
    Investigated Drugs:
    • Human Alpha1-Proteinase Inhibitor
    Denmark France Germany Ireland The Netherlands Poland +3

  • A Study of Sodium Selenite Followed by Chemotherapy in Patients with Advanced Cancer

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • Neoplasm malignant
    Investigated Drugs:
    • SODIUM SELENITE PENTAHYDRATE
    Sweden
Previous Page
1 … 68 69 70 71 72 … 1,646
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!